A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been
revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against …

The heterogeneity of the tumour immune microenvironment (TIME), organized by various
immune and stromal cells, is a major contributing factor of tumour metastasis, relapse and …

Background & Aims The tumour microenvironment (TME) is a crucial mediator of cancer
progression and therapeutic outcome. The TME subtype correlates with patient response to …

Aims Cuproptosis is a recently identified form of programmed cell death; however, its role in
hepatocellular carcinoma (HCC) remains unclear. Methods A set of bioinformatic tools was …

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …

Tumor microenvironments (TMEs) influence cancer progression but are complex and often
differ between patients. Considering that microenvironment variations may reveal rules …

Immune checkpoint inhibitor (ICI) therapy can induce complete responses in mismatch
repair-deficient and microsatellite instability-high (d-MMR/MSI-H) colorectal cancers (CRCs) …

Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M
NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC …

Immune checkpoint inhibitors (ICIs) have substantially improved the survival of cancer
patients over the past several years. However, only a minority of patients respond to ICI …